Loading
A phase 1/2 trial of CAR-GPC3 T Cells in hepatocellular carcinoma, non-small-cell lung cancer, merkel cell carcinoma and sarcomas, run by Sotio Biotech Inc., active and no longer recruiting.
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors is a phase 1/2 interventional study registered as NCT05120271 by Sotio Biotech Inc., with 7 participants enrolled, started 2022-10-26 and due to reach its primary completion in 2025-10-24. Interventions recorded: CAR-GPC3 T Cells.
Shares Sarcomas (soft tissue, bone, GIST), Non-small-cell lung cancer and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST), Non-small-cell lung cancer and the tag pipeline.
Shares Hepatocellular carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Hepatocellular carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Merkel cell carcinoma and the tag pipeline.